Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases

Neurotherapeutics

Volumn 14, Issue 1, 2017, Pages 135-147

  El Ayoubi, Nabil K ^a   Khoury, Samia J ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Autoimmune demyelination; Biomarkers; Disease progression; Multiple sclerosis; Therapeutic response

Indexed keywords

24 HYDROXYCHOLESTEROL; 25 HYDROXYVITAMIN D; ANTIGEN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHITINASE 3 LIKE PROTEIN 1; CHITINASE 3 LIKE PROTEIN 2; CHOLESTEROL; CXCL13 CHEMOKINE; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FAS LIGAND; GLYCOSIDASE; IMMUNOGLOBULIN G; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR4.1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICRORNA; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; NEUROFILAMENT PROTEIN; PROTEIN ANTIBODY; RECOMBINANT BETA INTERFERON; SCATTER FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA;

ANTIBODY BLOOD LEVEL; APOPTOSIS; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; MOLECULE; MULTIPLE SCLEROSIS; NEUROFILAMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SERUM; STANDARDIZATION; TREATMENT RESPONSE; BLOOD; COMPLICATION; DISEASE COURSE; ENCEPHALITIS;

BIOMARKERS; DISEASE PROGRESSION; ENCEPHALITIS; HUMANS; MULTIPLE SCLEROSIS;

EID: 84991730111     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0486-7     Document Type: Review

References (140)

1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
2. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2010;219:1–7.
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683–747.
4. Kasper LH, Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 2010;74:S2–S8.
5. Selmi C, Mix E, Zettl UK. A clear look at the neuroimmunology of multiple sclerosis and beyond. Autoimmun Rev 2012;11:159–162.
6. Wekerle H. Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 2008;67:56–60.
7. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res 2000;301:163–171.
8. Pender MP Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. J Neuroimmunol 2007;191:26–38.
9. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247–269.
10. Lassmann H. [Clinical and pathological topics of multiple sclerosis]. Rinsho Shinkeigaku 2009;49:715–718 (in Japanese).
11. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol 2010;225:2-8.
12. Lucchinetti C, BrückW, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
13. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115–121.
14. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210–218.
15. Kuhle J, Disanto G, Dobson, R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015; 21:1013–1024.
16. Wingerchuk D, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–189.
17. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of Natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87:117–125.
18. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.
19. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127:1463–1478.
20. Tumani H, Hartung HP, Hemmer B, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009;35:117–127.
21. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009;13:225–244.
22. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–846.
23. Tejera-Alhambra M, Casrouge A, De Andrés C, et al. Plasma biomarkers discriminate clinical forms of multiple sclerosis. PLOS ONE 2015;10:e0128952.
24. Fenoglio C, Ridolfi E, Cantoni C, et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler 2013;19:1938–1942.
25. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012;189:4175–4181.
26. Lv X, Jiang H, Liu Y, Lei X, Jiao J. MicroRNA-15b promotes neurogenesis and inhibits neural progenitor proliferation by directly repressing TET3 during early neocortical development. EMBO Rep 2014;15:1305–1314.
27. Cox MB, Cairns MJ, Gandhi KS, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLOS ONE 2010;5:e12132.
28. Keller A, Leidinger P, Steinmeyer F, et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler 2014;20:295–303.
29. Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 2012;39:6219–6225.
30. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211–217.
31. Kim S, Woodhall M, Kim J, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015;2:e163.
32. Tanaka M, Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 2014;270:98–99.
33. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2014;21:866–874.
34. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273–1277.
35. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008;105:18889–18894.
36. Quintana FJ, Patel B, Yeste A, et al. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology 2014;83:2219–2226.
37. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402–404.
38. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720–1725.
39. Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2008;14:59–66.
40. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2016;87:126–129.
41. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000;43:228–232.
42. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004;251:414–420.
43. Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 2004;363:14–17.
44. Bartosik-Psujek H, Stelmasiak Z. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J Neural Transm 2006;113:339–345.
45. Guimaraes I, Cardoso MI, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006;12:354–356.
46. Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007;115:325–330.
47. Brettschneider J, Maier M, Arda S, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005;11:261–265.
48. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367:115–123.
49. Kraus V, Srivastava R, Kalluri SR, et al. Potassium channel KIR4.1- specific antibodies in children with acquired demyelinating CNS disease. Neurology 2014;82:470–473.
50. Nerrant E, Salsac C, Charif M, et al. Lack of confirmation of antiinward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler 2014;20:1699–1703.
51. Brickshawana A, Hinson SR, Romero MF, et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 2013;13:795–806.
52. Brill L, Goldberg L, Karni A, et al. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse? Mult Scler 2015;21:572–579.
53. Leoni V, Masterman T, Diczfalusy U, et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002;331:163–166.
54. Teunissen CE, Dijkstra CD, Polman CH, et al. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci Lett 2003;347:159–162.
55. Van de Kraats C, Killestein J, Popescu V, et al. Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Mult Scler 2014;20:412–417.
56. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139–145.
57. Ketelslegers IA, Van Pelt DE, Bryde S, et al. MOG cell-based assay detects Non-MS Patients with inflammatory neurologic disease. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler 2015;21:1513–1520.
58. Cantó E, Tintoré M, Villar LM, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015;138:918-931.
59. Hinsinger G, Galéotti N, Nabholz N, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 2015;21:1251–1261.
60. Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007;115:137–146.
61. Festa ED, Hankiewicz K, Kim S, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult. Scler 2009;15:1271–1279.
62. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009;73:2003–2010.
63. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLOS ONE 2010;5:e11986.
64. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011;17:335–343.
65. Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011;17:819–829.
66. Martinelli V, Dalla CG, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014; 20:147–155.
67. Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and mri follow-up study. J Neuroimmunol 2011;234:141–147.
68. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132–139.
69. Silber E, Sharief M.K. Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 1999;170:11–18.
70. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003;60:219–223.
71. Ehling R, Lutterotti A, Wanschitz J, et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004;10:601–606.
72. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLOS ONE 2013;8:e75091.
73. Khalil M, Enzinger C, Langkammer C, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013;19:436–442.
74. Salzer J, Svenningsson A, Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287–292.
75. Trentini A, Comabella M, Tintoré M, et al. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014;261:2338–2343.
76. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016;54:1655–1661.
77. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2015;86:273–279.
78. Comabella M, Fernández M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133:1082–1093.
79. Sharief MK. Increased cellular expression of the caspase inhibitor FLIP in intrathecal lymphocytes from patients with multiple sclerosis. J Neuroimmunol 2000;111:203–209.
80. Semra YK, Seidi OA, Sharief M.K. Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis. J Neuroimmunol 2001;113:268–274.
81. Sharief MK, Noori MA, Douglas MR, Semra K. Upregulated surviving expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol 2002;9:503–510.
82. Inoue A, Koh CS, Sakai T, et al. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol 1997;75:141–146.
83. Huang W, Huang MP, Gomes MA, Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000;55:928–934.
84. Bilinska M, Frydecka I, Podemski R, Gruszka E. Fas expression on T cells and sFas in relapsing-remitting multiple sclerosis. Acta Neurol Scand 2003;107:387–393.
85. Gomes AC, Jonsson G, Mjornheim S, Olsson T, Hillert J, Grandien A. Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J Neuroimmunol 2003;135:126–134.
86. Mahovic D, Petravic D, Petelin Z, Zurak N, Horvat G, Hajnsek S. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis. Clin Neurol Neurosurg 2004;106:230–232.
87. Holman DW, Klein RS, Ransohoff RM. The Blood–brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta 2011;1812:220–230.
88. Kuenz B, Lutterotti A, Khalil M, et al. Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis. J Neuroimmunol 2005;167:143–149.
89. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999;122:191–197.
90. Waubant E, Goodkin D, Bostrom A, et al. IFN beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003;60:52–57.
91. Acar G, Idiman F, Idiman E, Kirkali G, Cakmakci H, Ozakbas S. Nitric oxide as an activity marker in multiple sclerosis. J Neurol 2003;250:588–592.
92. Rejdak K, Eikelenboom MJ, Petzold A, et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004;63:1439–1445.
93. Calabrese V, Scapagnini G, Ravagna A, et al. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 2002;70:580–587.
94. Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Sci 2008;265:93–96.
95. Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005;167:215–218.
96. Frota ER, Rodrigues DH, Donadi EA, Brum DG, Maciel DR, Teixeira AL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 2009;460:130–132.
97. Weinstock-Guttman B, Zivadinov R, Tamaño-Blanco M, et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol 2007;188:167–174.
98. Ottoboni L, Keenan BT, Tamayo P, et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 2012;4:153ra131.
99. Gandhi R, Healy B, Gholipour T, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013;73:729–740.
100. Kacperska MJ, Jastrzebski K, Tomasik B, Walenczak J, Konarska-Krol M, Glabinski A. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study. J Mol Neurosci 2015;56:154–163.
101. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflamm 2011;8:127.
102. Giubilei F, Antonini G, Di Legge S, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002;106:109–112.
103. Itay R, Webb J, Stuve O, et al. Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol 2015;11:69–91.
104. Lovelace, M.D., et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases, Neuropharmacology 2016 Mar 16 [Epub ahead of print].
105. Lovelace MD, Varney B, Sundaram G, et al. current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis. Front Immunol 2016;7:246.
106. Mancuso R, Hernis A, Agostini S, et al. Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing- remitting multiple sclerosis. PLOS ONE 2015;10:e0130715.
107. Ascherio A, Munger K, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71:306–314.
108. Mowry E, Pelletier D, Gao Z, Howell M, Zamvil S, Waubant E. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol 2016;23:327–332.
109. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740–750.
110. Buck D, Cepok S, Hoffmann S, et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011;68:480–487.
111. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Hum Genet 2008;83:219–227.
112. Hegen H, Millonig A, Bertolotto A, et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler 2014;20:577–587.
113. Gibbs E, Karim M E, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated patients with transient versus sustained NAbs. Clin Immunol 2014;157:91–101.
114. Graber JJ, Allie SR, Mullen KM, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008;196:124–132.
115. Matusevicius D, Kivisäkk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101–104.
116. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406–412.
117. Hartung HP, Steinman L, Goodin DS, et al. Interleukin 17F level and interferon β response in patients with multiple sclerosis. JAMA Neurol 2013;70:1017–1021.
118. Hecker M, Thamilarasan M, Koczan D, et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci 2013;14:16087–16110.
119. Liu X, Luo Y, Luo Z, Yang H. Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs. Neurochem Res 2014;39:1661–1674.
120. De Felice B, Mondola P, Sasso A, et al. Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β. BMC Med Genomics 2014;7:26.
121. Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013;19:593–600.
122. Lundkvist M, Engdahl E, Holmén C, et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler 2013;19:757–764.
123. Teunissen C, Malekzadeh A, Leurs C, Bridel C, Killestein J. Body fluid biomarkers for multiple sclerosis-the long road to clinical application. Nat Rev Neurol 2015;11:585–596.
124. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 2003;24:244–253.
125. Diehl GE, Yue HH, Hsieh K, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004;21:877–889.
126. Lunemann JD, Waiczies S, Ehrlich S, et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002;168:4881–4888.
127. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001;166:1314–1319.
128. Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036–2043.
129. Bartosik-Psujek H, Stelmasiak Z. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. J Neural Transm 2005;112:797-803.
130. Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand KV. Changes in blood B cell activating factor (BAFF) levels in multiple sclerosis: a sign of treatment outcome. PLOS ONE 2015;10:e0143393.
131. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-b increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131:1455–1463.
132. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-1880.
133. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies. Neurology 2007;69:1391–1403.
134. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802–812.
135. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in Natalizumab-treated MS patients. Neurology 2013;81:865–871.
136. Lieberman L, Zeng W, Singh C, et al. CD62L is not a reliable biomarker for predicting PML risk in Natalizumab-treated R-MS patients. Neurology 2016;86:375–381.
137. Schwab N, Schneider-Hohendorf T, Pignolet B, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler 2016;22:1048–1060.
138. Teunissen C, Menge T, Altintas A, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013;19:1802–1809.
139. Gnanapavan S, Hegen H, Khalil M, et al. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 2014;83:1210–1216.
140. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem 2014;47:288–292.